Showing 1,459 news articles about Pharmaceutical industry

Filters Content type: Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

New & experimental HIV treatments

Gilead’s single tablet regimen Odefsey receives European marketing approval for HIV treatment

Editor's pick
PharmaBiz
27 June 2016
Pharmaceutical industry

What Do Gilead And Martin Shkreli Have In Common?

Editor's pick
Seeking Alpha
22 June 2016
Pharmaceutical industry

Cipla in pact with Russian firm for HIV, Hepatitis C drugs

Editor's pick
Moneycontrol
20 June 2016
Pharmaceutical industry

HLM 2016 AIDS: Universal treatment access panel looks at issues in generic antiretroviral medicines

Editor's pick
Science Speaks
12 June 2016
Pharmaceutical industry

Gilead escapes liability in hepatitis C patent fight with Merck

Editor's pick
Reuters
7 June 2016
Hepatitis C treatment

Patients who pay £1,000 for life-saving drugs online that would cost NHS £35,000: More and more are doing it - but doctors warn it's a big risk

Editor's pick
Daily Mail
1 June 2016
Pharmaceutical industry

A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner

Editor's pick
Los Angeles Times
30 May 2016
New & experimental hepatitis C treatment

European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

Editor's pick
Gilled press relase
27 May 2016
Access to healthcare

Gilead's $1000 hepatitis C pill gets patent in India

Editor's pick
Times of India
10 May 2016
Pharmaceutical industry

Sky-high price of hepatitis C drug produces profits for lawmakers

Editor's pick
Center for Responsive Politics
5 May 2016
Pharmaceutical industry

'Aggressive' pricing helps Merck steal hep C share with newcomer Zepatier

Editor's pick
Fierce Pharma
3 May 2016
New & experimental HIV treatments

European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Editor's pick
Gilead press release
25 April 2016
PrEP

Gilead Statement on the Approval of PrEP in Peru

Editor's pick
Gilead Sciences
14 April 2016
Access to healthcare

Innovative new programme set to treat 10,000 patients co-infected with hepatitis C and HIV in Africa and Asia

Editor's pick
World Hepatitis Alliance
14 April 2016
Access to healthcare

PrEP Pricing Problems

Editor's pick
TAG
2 April 2016
Access to healthcare

Greed and the Necessity for Regulation

Editor's pick
TAG
2 April 2016
Pharmaceutical industry

GSK eases IP rights for poorest countries, considers patent pooling for cancer

Editor's pick
Intellectual Property Watch
2 April 2016
Finance & funding

Mortgages For Expensive Health Care? Some Experts Think It Can Work

Editor's pick
Kaiser Health News
29 March 2016
Drug-resistant TB

Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments

Editor's pick
Médecins Sans Frontières
24 March 2016
Pharmaceutical industry

Merck Wins Chance for Royalties on Gilead’s Hepatitis C Cure

Editor's pick
Bloomberg
24 March 2016
Access to healthcare

South African activists picket UN meeting for access to medicines

Editor's pick
Health-e
21 March 2016
Pharmaceutical industry

Inside the $100 million ad blitz for a $1100-a-pill drug for hepatitis C

Editor's pick
STAT
9 March 2016
Pharmaceutical industry

Gilead Spars With Merck Over Hepatitis C $1000-Pill Royalties

Editor's pick
Bloomberg
8 March 2016
Access to healthcare

UNITAID study looks at delinking cost of R&D from price of medicines

Editor's pick
UNITAID
2 March 2016